Company intelligence / Profile preview
VITRUVIAE
- Ownership
- Private
- Development stage
- Other
01
Overview
VITRUVIAE’s lead biotherapeutic, VTRU200, targets unique sugar and lipid patterns on cancer cells and viruses that are not present on normal cells. This approach aims to overcome drug resistance by focusing on cellular features that do not mutate or down-regulate like proteins. No clinical trial data has been published yet.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Biotherapeutics targeting sugar and lipid signatures (novel modality distinct from traditional small molecules or mAbs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on VITRUVIAE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VITRUVIAE.